Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larysa Shlapatska

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Immunology (Orlando, Fla.)|January 9, 2019
SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?Inna Gordiienko, Larysa Shlapatska, Larysa Kovalevska, et al.
Neoplasma|April 27, 2021
CD150 and CD180 are negative regulators of IL-10 expression and secretion in chronic lymphocytic leukemia B cellsValeriia Shcherbina, Inna Gordiienko, Larysa Shlapatska, et al.
Plos One|October 6, 2017
The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signalingInna Gordiienko, Larysa Shlapatska, Valeriia Kholodniuk, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Immunology (Orlando, Fla.)|January 9, 2019
SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?Inna Gordiienko, Larysa Shlapatska, Larysa Kovalevska, et al.
Neoplasma|April 27, 2021
CD150 and CD180 are negative regulators of IL-10 expression and secretion in chronic lymphocytic leukemia B cellsValeriia Shcherbina, Inna Gordiienko, Larysa Shlapatska, et al.
Plos One|October 6, 2017
The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signalingInna Gordiienko, Larysa Shlapatska, Valeriia Kholodniuk, et al.
Pageof 1